Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Ac...
April 11 2019 - 6:30AM
The highest risk of treatment failure is
seen in patients previously infected with a resistant
pathogen.
Iterum Therapeutics plc, (Nasdaq: ITRM) a clinical-stage
pharmaceutical company developing anti-infectives against
multi-drug resistant pathogens, will present three posters at the
European Congress of Clinical Microbiology & Infectious
Diseases (ECCMID) in Amsterdam, Netherlands on April 15, 2019.
“The rapidly rising rates of antibacterial
resistance in pathogens associated with uncomplicated urinary tract
infections are making successful treatment more challenging for
physicians while patients are experiencing more significant
clinical consequences,” said Michael Dunne, M.D., Chief Scientific
Officer of Iterum Therapeutics. “The elderly and those with
diabetes mellitus are especially at risk for treatment failure and
need better diagnostic and therapeutic options for this
disease.”
“As with urinary tract infections, the
prevalence of resistant gonorrhoeae infections is also on the rise.
We believe sulopenem, which is being developed in oral and
intravenous formulations, has considerable potential as an
important new treatment option to help patients and physicians
better address infections caused by resistant pathogens.”
Poster Presentation p1656. Session: Urinary
tract infections. 12:30 - 1:30PM CET
A patient-specific clinical predictive
model to anticipate the risk of treatment failure in uncomplicated
urinary tract infections
The authors reviewed the records of 4,792
patients given oral antibiotics for uncomplicated urinary tract
infections (uUTIs) and assessed the difference in 28-day outcomes
for patients with a uUTI whose pathogens were susceptible to
empiric therapy versus those who were non-susceptible to therapy,
highlighting the risk factors associated with failure. They
concluded:
- The most significant risk for treatment failure is treatment of
the index infection with an antibiotic to which the organism in a
prior infection was resistant.
- Age, gender and diabetes mellitus also increased the likelihood
of treatment failure.
- Treatment failure and hospitalization rates double with
mismatched empiric antibiotic therapy.
- The more antibiotic class resistance, the higher likelihood of
treatment failure.
Poster Presentation p1705. Session: Sexually
transmitted infections complicated by antimicrobial resistance.
12:30 -1:30PM CET.
In vitro activity of Sulopenem against
resistant Neisseria gonorrhoeae volunteers
- Sulopenem demonstrated in vitro activity against isolates of N.
gonorrhoeae non-susceptible to ceftriaxone and cefixime, as well as
those resistant to azithromycin or ciprofloxacin.
Poster Presentation p1992. Session: Evaluation
of diverse antimicrobials in vitro and experimental models. 1:30PM
- 2:30PM CET.
Post-antibiotic and sub-inhibitory
minimum inhibitory concentration effects of Sulopenem
- Sulopenem exhibited a post antibiotic-subMIC effect, which
potentially reflects additional antibacterial activity due to
exposure of the bacteria to higher concentrations of drug.
- Sulopenem may be active for a longer period of the dosing
interval than is defined simply by the amount of time the bacteria
is exposed to drug levels at the mean inhibitory
concentration.
The three posters will be available for review on Monday, April
15, 2019.
About Iterum Therapeutics plc
Iterum Therapeutics plc (Iterum Therapeutics) is an Irish
clinical-stage pharmaceutical company dedicated to developing
differentiated anti-infectives aimed at combatting the global
crisis of multi-drug resistant pathogens to significantly improve
the lives of people affected by serious and life-threatening
diseases around the world. Iterum Therapeutics is advancing its
first compound, sulopenem, a novel penem anti-infective compound
with oral and IV formulations that has demonstrated potent in vitro
activity against a wide variety of gram-negative, gram-positive and
anaerobic bacteria resistant to other antibiotics. Iterum
Therapeutics has received QIDP designations for its oral and IV
formulations for the treatment of uUTI, complicated urinary tract
infection and complicated intra-abdominal infection as well as
acute bacterial prostatitis, community-acquired bacterial
pneumonia, gonococcal urethritis and pelvic inflammatory disease.
For more information, please
visit http://www.iterumtx.com.
Forward-looking Statements
This press release may contain forward-looking
statements. These forward-looking statements include, without
limitation, statements regarding the development, therapeutic and
market potential of sulopenem. In some cases, forward-looking
statements can be identified by words such as “may,” “believes,”
“intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,”
“should,” “assumes,” “continues,” “could,” “will,” “future,”
“potential” or the negative of these or similar terms and phrases.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Iterum Therapeutics’
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements.
Forward-looking statements include all matters that are not
historical facts. Actual future results may be materially different
from what is expected due to factors largely outside Iterum
Therapeutics’ control, including the uncertainties inherent in the
initiation and conduct of clinical trials, clinical trial patient
enrollment, availability and timing of data from clinical trials,
changes in regulatory requirements or decisions of regulatory
authorities, the actions of third-party clinical research
organizations, suppliers and manufacturers, commercialization plans
and timelines, if approved, and other factors discussed under the
caption “Risk Factors” in its most recently filed Annual Report on
Form 10-K or Quarterly Report on Form 10-Q (as the case may be),
and other documents filed with the SEC from time to time.
Forward-looking statements represent Iterum Therapeutics’ beliefs
and assumptions only as of the date of this press release. Except
as required by law, Iterum Therapeutics assumes no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those
anticipated in the forward-looking statements, even if new
information becomes available in the future.
Investor Contact:Judy Matthews
Chief Financial Officer +1 312-778-6073 IR@iterumtx.com
Media Contact:Claire LaCagnina
6 Degrees 315-765-1462 clacagnina@6degreespr.com
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From Apr 2024 to May 2024
Iterum Therapeutics (NASDAQ:ITRM)
Historical Stock Chart
From May 2023 to May 2024